Intestinal research

Korean Association for the Study of the Intestinal Diseases (대한장연구학회)
권호 표지
DOI QR코드

DOI QR Code

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management

  • Park, Dong Il (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Hisamatsu, Tadakazu (The Third Department of Internal Medicine, Kyorin University School of Medicine) ;
  • Chen, Minhu (Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University) ;
  • Ng, Siew Chien (Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong) ;
  • Ooi, Choon Jin (Gleneagles Medical Centre and Duke-NUS Medical School) ;
  • Wei, Shu Chen (Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine) ;
  • Banerjee, Rupa (Department of Medical Gastroenterology, Asian Institute of Gastroenterology) ;
  • Hilmi, Ida Normiha (Department of Medicine, University of Malaya) ;
  • Jeen, Yoon Tae (Department of Internal Medicine, Korea University College of Medicine) ;
  • Han, Dong Soo (Department of Internal Medicine, Hanyang University Guri Hospital) ;
  • Kim, Hyo Jong (Department of Internal Medicine, Kyung Hee University School of Medicine) ;
  • Ran, Zhihua (Department of Gastroenterology, Shanghai Jiao Tong University) ;
  • Wu, Kaichun (Department of Gastroenterology, Fourth Military Medical University) ;
  • Qian, Jiaming (Department of Gastroenterology, Peking Union Medical College) ;
  • Hu, Pin-Jin (Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University) ;
  • Matsuoka, Katsuyoshi (Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University) ;
  • Andoh, Akira (Department of Gastroenterology, Shiga University) ;
  • Suzuki, Yasuo (Department of Internal Medicine, Toho University) ;
  • Sugano, Kentaro (Department of Medicine, Jichi Medical University) ;
  • Watanabe, Mamoru (Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University) ;
  • Hibi, Toshifumi (Center for Advanced IBD Research and Treatment, Kitasato University) ;
  • Puri, Amarender S. (Department of Gastroenterology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research) ;
  • Yang, Suk-Kyun (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2017.10.08
  • Accepted : 2017.10.13
  • Published : 2018.01.31
⟨ Previous Next ⟩

Abstract

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised 3 parts: management of latent TB in preparation for anti-TNF therapy, monitoring during anti-TNF therapy, and management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Keywords

Acknowledgement

Supported by : Ministry of Health & Welfare

References

  1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104. https://doi.org/10.1056/NEJMoa011110
  2. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active- surveillance report. Arthritis Rheum 2003;48:2122-2127. https://doi.org/10.1002/art.11137
  3. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014;53:1872-1885. https://doi.org/10.1093/rheumatology/keu172
  4. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014;91:47-55. https://doi.org/10.3899/jrheum.140102
  5. Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 2014;46:547-554. https://doi.org/10.3109/07853890.2014.941919
  6. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91. https://doi.org/10.1016/j.crohns.2009.02.010
  7. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-468. https://doi.org/10.1016/j.crohns.2013.12.013
  8. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563-1576. https://doi.org/10.1183/13993003.01245-2015
  9. Favalli EG, Caporali R, Sinigaglia L, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 2011;29(3 Suppl 66):S15-S27.
  10. Prevention Committee of the Japanese Society for Tuberculosis; Treatment Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis infection. Kekkaku 2014;89:21-37.
  11. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012;59:C4480.
  12. Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl 2014;91:41-46. https://doi.org/10.3899/jrheum.140101
  13. Carpio D, Jauregui-Amezaga A, de Francisco R, et al. Tuberculo-sis in anti-tumour necrosis factor-treated inflammatory bowel disease patients after the implementation of preventive measures: compliance with recommendations and safety of retreatment. J Crohns Colitis 2016;10:1186-1193. https://doi.org/10.1093/ecco-jcc/jjw022
  14. Bombardier C, Hazlewood GS, Akhavan P, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 2012;39:1583-1602. https://doi.org/10.3899/jrheum.120165
  15. Shim TS. Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy. Intest Res 2014;12:12-19. https://doi.org/10.5217/ir.2014.12.1.12
  16. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-805. https://doi.org/10.1136/thx.2005.046797
  17. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206. https://doi.org/10.1183/09031936.00028510
  18. Chebli JM, Gaburri PD, Chebli LA, et al. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-alpha therapy. Med Sci Monit 2014;20:487-498. https://doi.org/10.12659/MSM.890331
  19. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 2nd ed. Cheongju: Korean Centers for Disease Control and Prevention, 2014.
  20. Hsia EC, Schluger N, Cush JJ, et al. Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-2077. https://doi.org/10.1002/art.34382
  21. Denis B, Lefort A, Flipo RM, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 2008;14:183-186. https://doi.org/10.1111/j.1469-0691.2007.01891.x
  22. Updated recommendations for the use of biological agents for the treatment of rheumatic diseases. Australian Rheumatology Association Web site. http://www.rheumatology.org.au/downloads/. Accessed March 29, 2017.
  23. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791. https://doi.org/10.1136/ard.62.8.791
  24. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-1772. https://doi.org/10.1002/art.21043
  25. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-622.
  26. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-S247. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  27. Park SJ, Jo KW, Yoo B, et al. Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy. Int J Tuberc Lung Dis 2015;19:342-348. https://doi.org/10.5588/ijtld.14.0554
  28. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009;49:1883-1889. https://doi.org/10.1086/647944
  29. Al Jahdali HH, Baharoon S, Abba AA, et al. Saudi guidelines for testing and treatment of latent tuberculosis infection. Ann Saudi Med 2010;30:38-49. https://doi.org/10.4103/0256-4947.59373
  30. Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
  31. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-2166. https://doi.org/10.1056/NEJMoa1104875
  32. Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014;161:419-428. https://doi.org/10.7326/M14-1019
  33. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850.
  34. Gomez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-761. https://doi.org/10.1002/art.22768
  35. Lee JW, Choi CH, Park JH, et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intest Res 2016;14:146-151. https://doi.org/10.5217/ir.2016.14.2.146
  36. Jauregui-Amezaga A, Turon F, Ordas I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013;7:208-212. https://doi.org/10.1016/j.crohns.2012.05.012
  37. Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J, Ponce-de-Leon-Garduno A, Diaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases: a case-control study. Clin Exp Rheumatol 1999;17:81-87.
  38. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003;29:2327-2329. https://doi.org/10.1007/s00134-003-1867-z
  39. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007;4:e120. doi: 10.1371/journal.pmed.0040120.
  40. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-1132.
  41. Kwon M, Sung M, Kwon YJ, et al. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis. J Clin Rheumatol 2014;20:68-73. https://doi.org/10.1097/RHU.0000000000000074
  42. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008;13:468-472. https://doi.org/10.1111/j.1440-1843.2008.01244.x
  43. Kim KH, Lee SW, Chung WT, et al. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 2011;31:271-278. https://doi.org/10.3343/kjlm.2011.31.4.271
  44. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-1265. https://doi.org/10.1086/383317
  45. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-639. https://doi.org/10.1002/acr.21641
  46. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-2163. https://doi.org/10.3899/jrheum.090150
  47. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. Ann Rheum Dis 2012;71:231-237. https://doi.org/10.1136/annrheumdis-2011-200489
  48. Papay P, Primas C, Eser A, et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-alpha inhibitors. Aliment Pharmacol Ther 2012;36:858-865. https://doi.org/10.1111/apt.12037
  49. Hatzara C, Hadziyannis E, Kandili A, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 2015;74:1848-1853. https://doi.org/10.1136/annrheumdis-2014-205376
  50. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21. https://doi.org/10.1164/ajrccm.159.1.9801120
  51. Anibarro L, Trigo M, Villaverde C, et al. Interferon-gamma release assays in tuberculosis contacts: is there a window period? Eur Respir J 2011;37:215-217. https://doi.org/10.1183/09031936.00030610
  52. Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013;7:e486-e492. doi: 10.1016/j.crohns.2013.03.004.
  53. Abitbol Y, Laharie D, Cosnes J, et al. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohns Colitis 2016;10:1179-1185. https://doi.org/10.1093/ecco-jcc/jjw129
  54. Debeuckelaere C, De Munter P, Van Bleyenbergh P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis 2014;8:550-557. https://doi.org/10.1016/j.crohns.2013.11.008
  55. Newton SM, Mackie SL, Martineau AR, et al. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin Vaccine Immunol 2008;15:506-512. https://doi.org/10.1128/CVI.00401-07
  56. Chakravarty SD, Zhu G, Tsai MC, et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008;76:916-926. https://doi.org/10.1128/IAI.01011-07
  57. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005;41 Suppl 3:S189-S193. https://doi.org/10.1086/429994
  58. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:19-30.
  59. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004;18:257-264. https://doi.org/10.1097/00002030-200401230-00015
  60. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005;191:856-865. https://doi.org/10.1086/427995
  61. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005;40:756-759. https://doi.org/10.1086/427941
  62. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008;68:191-208. https://doi.org/10.2165/00003495-200868020-00004
  63. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-1359. https://doi.org/10.2165/00003495-200059060-00010
  64. Rivoisy C, Tubach F, Roy C, et al. Paradoxical anti-TNF-associated TB worsening: frequency and factors associated with IRIS. Joint Bone Spine 2016;83:173-178. https://doi.org/10.1016/j.jbspin.2015.04.022
  65. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008;47:e83-e85. doi: 10.1086/592695.

Cited by

  1. Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis vol.74, pp.3, 2019, https://doi.org/10.4166/kjg.2019.74.3.168
  2. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease vol.34, pp.10, 2018, https://doi.org/10.1007/s00384-019-03368-1
  3. Translating the gut microbiome: ready for the clinic? vol.16, pp.11, 2018, https://doi.org/10.1038/s41575-019-0204-0
  4. Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease vol.75, pp.1, 2020, https://doi.org/10.4166/kjg.2020.75.1.1
  5. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy vol.75, pp.1, 2020, https://doi.org/10.4166/kjg.2020.75.1.29
  6. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries vol.14, pp.6, 2018, https://doi.org/10.5009/gnl19209
  7. Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab vol.38, pp.3, 2018, https://doi.org/10.12701/yujm.2020.00878
  8. Current status of inflammatory bowel diseases in Korea vol.64, pp.9, 2018, https://doi.org/10.5124/jkma.2021.64.9.572